Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Acute 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Thrombosis 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Recurrence 2Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Disease 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Thrombophilia 1Thrombocytopenia 1Thoracic Neoplasms 1Skin Neoplasms 1Pituitary Neoplasms 1Pediatric Solid Tumor, Unspecified, Protocol Specific 1Papillomavirus Infections 1

Interventions

durvalumab 1Injections 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Advanced Biliary Tract Cancer × Injections × Clear all
NCT07229625 2026-01-28

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
604 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡